Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

NCT05058651 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

189

Enrollment

NIH

Sponsor class

Conditions

Advanced Extrapulmonary Neuroendocrine Carcinoma
Metastatic Extrapulmonary Neuroendocrine Carcinoma
Recurrent Extrapulmonary Neuroendocrine Carcinoma
Unresectable Extrapulmonary Neuroendocrine Carcinoma

Interventions

BIOLOGICAL: Atezolizumab
PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
DRUG: Cisplatin
PROCEDURE: Computed Tomography
DRUG: Etoposide
PROCEDURE: Magnetic Resonance Imaging
OTHER: Patient Observation

Sponsor

National Cancer Institute (NCI)